Dare Bioscience (DARE) Share-based Compensation (2013 - 2025)
Dare Bioscience's (DARE) quarterly Share-based Compensation came in at $400000.0 in Q4 2025, down 18.24% YoY from $489260.0 in Q4 2024, and down 0.75% on a QoQ basis from $403027.0 in Q3 2025.
Dare Bioscience (DARE) Share-based Compensation (2013 - 2025) Analysis & Trends
Dare Bioscience (DARE) has 13 years of Share-based Compensation data on file, last reported at $400000.0 in Q4 2025.
- Quarterly Share-based Compensation fell 18.24% year-over-year to $400000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.5 million (down 30.13% YoY) and the FY2025 annual result came in at $407534.0, down 81.5% from the prior year.
- Share-based Compensation fell to $400000.0 in Q4 2025, from $403027.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.5 million in Q4 2023 to a low of -$1.3 million in Q3 2023.
- A 5-year average of $469943.1 and a median of $506419.0 in 2024 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 343.23% in 2023, down 329.1% in 2023.
- Tracing DARE's Share-based Compensation over 5 years: stood at $1.3 million in 2021, then slumped by 180.58% to -$1.0 million in 2022, then surged by 343.23% to $2.5 million in 2023, then slumped by 80.67% to $489260.0 in 2024, then retreated by 18.24% to $400000.0 in 2025.
- The last three Share-based Compensation figures came in at $400000.0 (Q4 2025), $403027.0 (Q3 2025), and $736375.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Dare Bioscience | 11.91 Mn | -705,728.22 | -132,343.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 400,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Sep 30, 2025 | 403,027.00 |
| Sep 30, 2025 | 403,027.00 |
| Jun 30, 2025 | 736,375.00 |
| Jun 30, 2025 | 736,375.00 |
| Dec 31, 2024 | 489,260.00 |
| Dec 31, 2024 | 489,260.00 |
| Sep 30, 2024 | 523,578.00 |
| Sep 30, 2024 | 523,578.00 |
| Jun 30, 2024 | 790,418.00 |
| Jun 30, 2024 | 790,418.00 |
| Mar 31, 2024 | 400,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Dec 31, 2023 | 2.53 Mn |
| Dec 31, 2023 | 2.53 Mn |
| Sep 30, 2023 | -1.27 Mn |
| Sep 30, 2023 | -1.27 Mn |
| Jun 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 1.27 Mn |